NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue [Yahoo! Finance]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Yahoo! Finance
– Announces Chief Financial Officer transition – FORT MYERS, Fla., January 12, 2026 BUSINESS WIRE NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue For the fourth quarter of 2025, NeoGenomics expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, NeoGenomics expects to report total revenue of approximately $727 million, representing year-over-year growth of 10%. "Our preliminary fourth quarter revenue reflects our ongoing commitment to being the cancer testing ‘partner of choice' to pathologists and oncologists in the community setting, where approximately 80% of cancer care is delivered today," stated Tony Zook, CEO of NeoGenomic
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics (NASDAQ:NEO) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.MarketBeat
- NeoGenomics sees Q4 revenue of about $190M [Seeking Alpha]Seeking Alpha
- NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 RevenueBusiness Wire
- NeoGenomics (NASDAQ:NEO) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- A Look At NeoGenomics (NEO) Valuation After Recent Share Price Momentum Shift [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 10/28/25 - Beat
NEO
Sec Filings
- 1/12/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 3
- NEO's page on the SEC website